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Head and neck cancer is one of the most frequent malignances worldwide. Despite the site-specific mul-
timodality therapy, up to half of the patients will develop recurrence. Treatment selection based on a
multidisciplinary tumor board represents the cornerstone of head and neck cancer, as it is essential for
achieving the best results, not only in terms of outcome, but also in terms of organ-function preservation
and quality of life. Evidence-based international and national clinical practice guidelines for head and
neck cancer not always provide answers in terms of decision-making that specialists must deal with in
their daily practice. This is the first Expert Consensus on the Multidisciplinary Approach for Head and
Neck Squamous Cell Carcinoma (HNSCC) elaborated by the Spanish Society for Head and Neck Cancer
and based on a Delphi methodology. It offers several specific recommendations based on the available
evidence and the expertise of our specialists to facilitate decision-making of all health-care specialists
involved.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
HNSCC is the fifth most common malignancy worldwide and
the eighth most common cause of cancer-related mortality [1,2].
Tobacco and alcohol abuse are the main risk factors, but in the past
few years HPV infection has emerged as a new risk factor for a sub-
stantial percentage of HNSCC-especially in oropharyngeal cancer(OPC) [3]. Only one third of the patients present with early stage
disease, while most of themwill have locally advanced (LA) disease
by the time of diagnosis [4]. In these patients, 5-year survival has
remained invariable in the last decades [5]. Surgery and radiother-
apy (RT) remain the primary treatment modalities for early
tumors, while the addition of chemotherapy and targeted therapy
(anti-EGFR monoclonal antibody Cetuximab) improve survival in
locoregionally advanced disease [6,7]. However, despite the site-
specific multimodality therapy, up to 60% and 30% of patients will
develop local and distant recurrence, respectively [8]. Treatment
selection based on a multidisciplinary tumor board decision repre-
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achieving the best results, not only in terms of outcome, but also in
terms of organ-function preservation and quality of life [9,10].
Evidence-based international and national guidelines for Head
and Neck cancer are helpful but they often do not provide answers
in terms of decision-making that specialists must deal with in their
daily practice [10,11]. In this regard, an expert consensus might
represent a useful tool. There is only one expert consensus on
the multidisciplinary treatment for HNSCC, published by Lang in
2014, although its elaboration was not based on a ‘‘Delphi”
methodology [12]. This is the first Expert Consensus on the Mul-
tidisciplinary Approach for HNSCC Treatment elaborated by the
Spanish Society for Head and Neck Cancer that offers several speci-
fic recommendations based on the available evidence and the
expertise of our specialists to facilitate decision-making of all
health-care specialists involved.Methods
The first ‘‘Consensus on the Multidisciplinary Approach for
HNSCC Treatment” was endorsed by the Spanish Group for Head
and Neck Cancer Treatment (TTCC) and the Spanish Society for
Head and Neck (SECC), including medical, radiation and surgical
oncologists.
The study was performed using the Delphi methodology; a sys-
tematic, interactive forecasting method which relies on a panel of
experts integrated in this study by 25 specialists whose contribu-
tions were collected in the form of answers to questionnaires
and their comments. The group of experts was led by the four
authors of the article: MR and RA (medical oncologists), president
and vice-president of the Spanish Group for Head and Neck Cancer
Treatment (TTCC) respectively; GJ (radiation oncologist), president
of the Spanish Group of Radiation Oncology for Head and Neck
Cancer (GEORCC); and MM (ENT) Head of Head and Neck Cancer
from the Spanish Society of Otorhinolaryngology (SEORL). The 25
experts participating were selected based on the following criteria:
Opinion leadership in their own area, experience in the field (a
minimum of 5 years-experience in Head and Neck cancer) and geo-
graphical location (to cover or the Spanish geography). A coordina-
tor controlled the interactions among the participants by
processing the information and filtering out irrelevant content.
The result is a number of recommendations obtained from a
decision-making process by a structured expert group, which are
believed to be more accurate than those from unstructured groups
or individuals. To that end, to achieve a consensus of agreement, in
the case of questions based on a metric scale, the level of consensus
required in each question must be equal to or greater than 68% in
the first phase, and equal to or greater than 70% in the second
phase in the ‘‘TOP 4” (meaning a minimum score of 7 points).
The same rule applies for a consensus of disagreement that is
achieved when in the second phase the ‘‘BOTTOM 4” meaning a
maximum score of 3 points. In the case of nominal questions, a
level of consensus equal or greater than 50% is required to achieve
a consensus of agreement or disagreement.
A total of 57 questions were elaborated by the coordinators and
distributed in 6 categories (C): 1. Laryngeal/hypopharyngeal can-
cer; 2. OPC and oral cavity cancer (OCC); 3. Response assessment
after a non-surgical treatment; 4. Recurrent/metastatic disease;
5. Relapse and second primary tumors; 6. Cervical SCC of unknown
primary site.
The study was developed in 3 phases. During the first phase,
developed between February 12th and March 14th, 2016, the
experts answered the 57 questions anonymously through an
online questionnaire. Questions that did not reach the level of con-
sensus required in the first phase were proposed for inclusion inthe second phase, developed between April 13th and May 3rd. In
this phase questions were answered again by 21 of the 25 partici-
pating experts. In the third phase, developed between June 8th and
20th, experts had to answer 4 additional questions proposed by the
coordinators: 22 of the 25 initial experts participated in this phase.
The coordinators were responsible for the analysis and identifica-
tion of the divergent answers and did not respond the questions
in any phase of the study. Finally, once elaborated the recommen-
dations, experts validated every recommendation by voting in a
face-to-face meeting.
This first article is focused on the following categories (C): early
stage and locally advanced HNSCC (C1, C2) and evaluation of
response after CRT (C3).Results and discussion
C1. Laryngeal/hypopharyngeal SCC
See Table 1.C1.A Early stage (stage I and II)
Clinical staging using diagnostic imaging is necessary to plan
the optimal therapeutic approach, which should ensure the radical
management of oncological patients [13]. Indirect laryngoscopy is
the first step in the diagnosis and clinical evaluation of laryngeal
cancer (tumor extension), however, it has limitations in the assess-
ment of the implication of deep structures (anterior commissure,
thyroid cartilage, and paraglottic spaces) that are discriminating
for the extension of surgical resection [14]. This is especially rele-
vant to offer partial resections or RT, which have demonstrated
high rates of local control. CT and MRI are useful imaging tests with
similar sensitivity to detect the extension of cartilage invasion and
nodal involvement [15]. As a result, the panel of experts recom-
mend an imaging test (CT or MRI) in the routine staging of early
laryngeal/hypopharyngeal cancer.
Treatment of choice for an early stage laryngeal/hypopharyn-
geal cancer should be the most effective in terms of outcome
according to the available evidence, and should not be influenced
by further potential salvage therapies. When feasible, organ-
preservation strategies including RT, partial laryngectomy (PL) or
transoral laser surgery (TOLS) should be the initial therapeutic
approach. Although there are no randomized trials comparing RT
and conservation surgery, both strategies have shown similar rates
in terms of local control (LC), progression-free survival (PFS) and
overall survival (OS) [16]. In case of surgery, a margin of 2 mm is
considered correct in early glottic cancer [17,18]. TOLS might
achieve higher rates of local control and larynx preservation in
some series and it has shown to improve overall survival when
compared to RT in a meta-analysis of early-stage glottic cancer
[19,20]. Adjuvant RT has not shown any benefit and might limit
its further use at recurrence. Consequently, the experts agree that
both modalities are valid in this setting, but recommend TOLS as
treatment of choice for stage I/II laryngeal cancer. In stage I laryn-
geal cancer involving anterior commissure, that differs from the T1
reaching anterior commissure because of infiltration of cartilage,
similar control rates can be obtained with open surgery, TOLS or
RT, although some authors report that TOLS seemed to be associ-
ated with a higher risk of positive margins. [21–23].
Voice quality should also be considered when choosing the best
treatment approach, especially in patients who need to preserve
their voice for occupational purposes. Most studies suggest that
RT improves functional outcomes and is better at preserving voice
quality, especially in supraglottic cancers. Surgery of glottic cancer
is associated with greater rates of dysphonia, which seem to be
related to the extension of resection and the type of cordectomy
Table 1
Summary of recommendations for Laryngeal and Hypopharyngeal cancer.
Recommendation Phase Accepted consensus
(% of agreement)
Routine staging of early laryngeal/
hypopharyngeal cancers should include an
imaging test
1 YES (72)
Initial treatment of choice for laryngeal/
hypopharyngeal cancer should be the
most effective according to available
evidence, and should not be influenced by
further potential salvage therapies
2 YES (76)
First treatment approach for an early stage
laryngeal/hypopharyngeal cancer should
include either surgery or radiotherapy, but
not the combination of both
1 YES (80)
Transoral surgery is the recommended
treatment for stage I/II laryngeal cancer
1 YES (88)
Adjuvant radiotherapy is generally not
recommended
YES (72)
Treatment required for carcinomas located in
the anterior commissure differs from the
T1b glottis carcinoma
1 YES (76)
Voice quality should be considered when
choosing the treatment for a stage I/II
laryngeal/hypopharyngeal cancer
1 YES (88)
Radiotherapy should be the treatment of
choice for patients diagnosed with an
early stage glottis cancer who need to
preserve their voice for occupational
purposes
1 YES (92)
Patients with positive resection margins after
surgery with radical intention for a
laryngeal/hypopharyngeal cancer should
be offered surgical:
1 YES
– Re-resection (92)
– If not feasible, adjuvant radiotherapy is
recommended
(68)
– Observation is not recommended (68)
In patients with locally advanced supraglottic
cancer either:
YES
– surgery (supraglottic laryngectomy) 2 (76)
– concurrent chemoradiotherapy 1 (88)
are validated options of treatment
In patients with laryngeal/hypopharyngeal
cancer, nodal disease burden (N) might
change the initial therapeutic approach of
the primary tumor, regardless of the T
stage
1 YES (92)
In patients with a T3 laryngeal/
hypopharyngeal cancer, concurrent
chemoradiotherapy (CRT) is
recommended
1 YES (88)
Total or partial laryngectomy is an adequate
treatment option in patients with a T3
laryngeal/hypopharyngeal cancer
2 NO (33)
Surgery followed by adjuvant radiotherapy/
CRT should be the treatment of choice for
T4 laryngeal/hypopharyngeal cancer.
2 YES (81)
The treatment of choice when avoiding a
pharyngolaryngectomy should be:
NO
concurrent CRT 2 (72)
induction chemotherapy (ICT) (62)
Weekly Cisplatin at a dose of 40 mg/m2
should not be used concurrent with
radiotherapy
1 YES (95)
In case of ICT as a treatment of choice for
locally advanced laryngeal/
hypopharyngeal cancer, a tumor reduction
greater than 50% in the evaluation of
response is needed to continue with the
organ-preservation approach
1 YES (92)
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choice in patients who need to preserve their voice for professional
purposes.
Surgery should ensure the complete removal of the tumor with
clear margins, as positive margins are an independent risk factorfor high local recurrence, disease-free survival (DFS) and OS. Con-
sequently, in the event of positive margins after surgery, further
treatments should always be given. It is unclear whether re-
resection or RT are the optimal treatment in this scenario. In
patients with close or positive margins who received post-
operative RT, fewer recurrences not statistically significant have
been reported. Despite this, some authors as Crespo et al., suggest
that surgical re-treatment is the preferred option to avoid the addi-
tional morbidity of RT and to reserve this treatment for the future
[25]. The authors of this consensus recommend surgery as treat-
ment of choice in case of positive margins, leaving RT as the alter-
native option when surgery is not feasible.
C1.B. Locally advanced (stage III/IVb)
Treatment for locoregionally advanced laryngeal and hypopha-
ryngeal SCC entails high complexity as different variables must be
considered: patient’s performance status, comorbidities, patient
preferences, tumor localization, stage and resectability. Therefore,
a multidisciplinary tumor board is essential to choose the best
therapeutic approach. The goals are to achieve the best results in
terms of outcome and to preserve organ function when feasible.
American and European guidelines recommend an organ-
preservation approach as initial treatment of choice, which usually
involves a combination of chemotherapy (CT) and RT, based on the
Intergroup RTOG 91-11 trial, which established a new standard for
larynx preservation (LP) by demonstrating the superiority of con-
comitant cisplatin plus RT for achieving LC and LP regarding other
regimens, and with equivalent survival outcomes compared to sur-
gery followed by RT ± CT [26–28]. On the other hand, some studies
suggested that the decrease of survival recorded for larynx cancer
in the mid-1990s may be related to changes in patterns of manage-
ment (Hoffman et al., 2006). It must be considered that salvage
surgery at recurrence after CRT entails a higher risk of major com-
plications. Surgery (including total or PL) is a valid option but it is
usually reserved to treat locoregional recurrences after conserva-
tive treatment or in patients who are not eligible or want to avoid
chemoradiotherapy (CRT). In this regard, the experts recommend
concurrent CRT as the initial treatment of choice for locally-
advanced T3 laryngeal/hypopharyngeal cancer, though there was
no consensus on whether total or PL is an adequate treatment
option in this setting. However, in the case of supraglottic cancer,
they agree that supraglottic laryngectomy is a valid alternative in
selected patients.
It must be considered that locally advanced disease is defined
not only by the primary tumor (T), but also by nodal burden (N).
In selected patients with small primary tumors but high nodal dis-
ease, preservation surgery followed by adjuvant RT or CRT can
achieve similar results in terms of disease control, although there
are no randomized trials comparing both strategies [26,29]. Conse-
quently, the authors of this consensus consider that nodal disease
burden (N) might change the initial therapeutic approach of the
primary tumor, regardless of the T stage.
Treatment for T4 laryngeal or hypopharyngeal cancer is a sub-
ject of discussion. There is no actual level I evidence to support
non-operative organ preservation strategy. Patients with T4a dis-
ease and penetration through cartilage were not included in
RTOG91-11. In the VALCSG trial, more than half of the patients
with T4 disease underwent laryngectomy, and those randomized
to laryngectomy had better survival [26,27,31]. Data from retro-
spective studies has given rise to controversy, with some reporting
a decline in OS in patients treated with CRT, while others found no
difference [26,30,32]. Therefore, the panel recommend surgery fol-
lowed by RT as the treatment of choice for T4 laryngeal/hypopha-
ryngeal cancer.
The role of induction chemotherapy (ICT) is still a matter
of debate. The authors did not reach a consensus on whether
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should be the treatment of choice when a pharyngolaryngectomy
is to be avoided. The EORTC trial 24891 published by Lefebvre in
1996 comparing surgery to ICT (cisplatin plus fluorouracil) fol-
lowed by radiation as a larynx-preservation strategy showed that
both treatments were equivalent in terms of survival and almost
the half of patients in the induction arm preserved a functional lar-
ynx [33]. These results were maintained at 10 years of follow-up
[34]. A meta-analysis published by Pignon et al. showed an abso-
lute OS benefit of 5% when using ICT (cisplatin plus fluorouracil
regimen) [35,36]. This benefit has been increased by the addition
of taxanes to the regimen, which also improves complete response
(CR) rates and decreases the incidence of distant metastases, as
reported in two randomized trials and a meta-analysis [37–40].
However, the remarkable hematological toxicity of this regimen,
and the publication of a recent meta-analysis that showed no sta-
tistically significant differences in OS, PFS or locoregional control,
has given rise to this debate [41]. Clearly, tumor response to ICT
has a prognostic and predictive value [38–40]. In this regard, the
authors agree that in patients selected for ICT, a tumor reduction
greater than 50% in the evaluation of response is needed to con-
tinue with the organ-preservation approach.
When it comes to CRT, weekly cisplatin at a dose of 40 mg/m2
should not be used concurrent with RT, since there are no phase
III randomized trials comparing this regimen to the standard regi-
men of three-weekly cisplatin at a dose of 100 mg/m2. A recent
meta-analysis comparing the efficacy and toxicity of both regimens
found that weekly cisplatin was associated with less gastrointesti-
nal toxicities but more grade 3 mucositis and chemotherapy
related delay, with no differences in OS or LC [42].
C2. OPC and OCC
See Table 2.
C2.A Early stage OPC and OCC
Therapeutic options for early stage oropharyngeal squamous
cell carcinoma (OPSCC) include both surgery and RT as single treat-
ment modality. Both have shown equivalent LC and survival across
the studies, but there are no randomized trials comparing both
approaches [43]. In this regard, some authors suggest that two
main factors must be considered when choosing the best treat-
ment: HPV status and functional outcome following treatment
and associated complications, especially late complications. HPV-
related oropharyngeal tumors represent a distinct entity with dif-
ferent clinical and molecular features and treatment responsive-
ness [44]. They are usually associated to non-smoking younger
patients, and show an overall better prognosis to any treatment
for a given stage [3,44]. In consequence, there is a growing interest
in the development of treatment deintensification trials to
decrease treatment-related morbidity and functional impairment
without compromising efficacy, although current evidence does
not support less intense therapy compared with HPV-negative
OPC. Intensity-modulated RT (IMRT) has improved radiation-
induced late toxicity effects (xerostomia, trismus, osteoradionecro-
sis) so it might be a suitable option in early stage OPC [3,43]. Sur-
gery approaches have also changed: classically, open head and
neck surgery has been the state of the art procedure, with all the
morbidity that it might involve (scars, malocclusion, compromised
swallowing, chronic aspiration, and altered speech articulation);
since the development of transoral endoscopic surgery, including
transoral laser microsurgery (TLM) and transoral robotic surgery
(TORS), which provide improved functional outcomes with mini-
mal surgical morbidity, surgery might be also an adequate first
treatment approach [45]. Moreover, surgery has the advantage to
offer pathologic staging to selectively intensify high-risk patientsfor improved survival [46]. The experts did not reach a consensus
on whether RT or surgery should be the treatment of choice for
early stage OPC, however, RT was preferred over surgery as first
treatment option for HPV-positive early stage OPC, while surgery
was preferred over RT for HPV-negative OPC. As discussed in C1.
A, in case of positive margins, surgical re-treatment is preferred
over RT to avoid additional morbidity and to reserve this treatment
for the future.
The role of adjuvant RT and CT is clear in locally advanced dis-
ease [46,50,51], but there is less evidence supporting its use in
early stages. Post-operative RT has shown benefit in survival in
early stage OPC when major adverse features (nodal metastasis,
positive margins) are present [46,49], but its role is less clear in
the presence of minor adverse features which include the degree
of tumor differentiation, lymphovascular invasion, perineural inva-
sion and, depending on the authors, tumor depth of invasion. The
presence of this features, especially perineural invasion, are classi-
cal negative prognostic factors for DFS and OS [47,48]. There are no
randomized trials evaluating the role of postoperative RT in this
setting, however, small retrospective series have shown an
improvement in survival when adding RT [49]. Therefore, the panel
recommends adjuvant RT after resection of a stage I/II OPC if 2 or
more minor adverse factors or if isolated perineural invasion are
present in the resected tumor.
The addition of CT to adjuvant RT has been evaluated in two
phase III randomized trials, the RTOG 9501 and EORTC 2293
[46,50]. Both trials were designed to evaluate adjuvant CRT in
patients with locally advanced disease (stage III and IVa) that pre-
sented with major adverse features: extracapsular nodal spread
and positive margins. However, in the EORTC trial, tumors with
perineural invasion and few early stage tumors (T1-2 N0-1) were
included. This study showed that the addition of systemic therapy
improves DFS and OS. A retrospective analysis of both trials con-
firmed that adjuvant CRT improved the locoregional control rate,
DFS and OS in patients that presented extracapsular nodal spread
and positive margins [51]. As a result, the experts agree that
patients with resected stage I/II OPC should receive adjuvant CRT
when extracapsular spread is present in any of the lymph nodes
resected. In the event the patient is not amenable for chemother-
apy, then RT alone is recommended.
The oral cavity is a distinct site that possesses a complex func-
tional anatomy and, despite its proximity to the oropharynx,
tumors have a different etiology, management and outcome [52].
Surgery is often the first modality in sequential therapy because
definitive high-dose radiation is associated with higher rates of
osteoradionecrosis (ORN) compared with doses for postoperative
adjuvant therapy [53,54]. Therefore, the panel of experts recom-
mend surgery as treatment of choice for patients with early stage
(I/II) OCC. Indications for adjuvant RT and CRT in OPC are applica-
ble in OCC.
C2.B. Locally advanced OPC and OCC
To date, there are no prospective trials comparing surgery to
definitive CRT in locally advanced OCC. Most of the data of organ
preservation strategies in OCC come from clinical trials for locally
advanced HNSCC in which very reduced groups of OCCs were
included as clinicians were reluctant to enroll these patients due
to the expectation of high toxicity and poor functional outcome.
Few retrospective studies evaluated the results of the OCC cohorts
from these trials showing similar efficacy in terms of survival when
compared to surgery followed by perioperative RT or CRT, with PFS
and OS rates ranging from 50% to 80% and 35% to 70% at 5 years,
respectively [55–57]. Efficacy was maintained across stage III and
IV and in patients with cartilage or bone invasion [55,61], but acute
and late toxicity across the studies was remarkable, especially
ORN, with rates ranging between 10% and 20% [53,54,62]. In two
Table 2
Summary of recommendations for OPC and OCC.
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metastases when compared to surgery plus postoperative CRT
[60,61], but responders had improved outcomes, and some
patients with T4 tumors might avoid total glossectomy [58,59].
However, level I data suggest that ICT has limited benefit, and
CRT has not been evaluated in adequately powered studies that
permit definitive recommendations, whereas surgery remains the
standard of care. Consequently, the panel recommends surgery
over concurrent CRT in patients with locally advanced oral cavity
tumors (stage III/IVA) that are resectable but subsequent recon-
struction is expected.
Conversely, for locally-advanced OPC (stage III-IVa-b), both
American and European guidelines recommend CRT over surgery
(10, quote ESMO guidelines). Radiation with concurrent cisplatin
is the standard of care in this setting. As discussed above, cisplatin
at a dose of 100 mg/m2 every three weeks is the standard regimen,
as there is no level I evidence to support other agents nor other
schedules (see C1B). There is no current evidence to support less
intense therapy for HPV-positive OPC either [63]. ICT remains a
subject of discussion. Results from randomized trials comparing
both strategies and a recent meta-analysis have failed to show a
survival advantage of ICT in this group of patients, despite higher
response rates and lower rates of distant metastases [40,64–66].
A recent review by Shert et al. evaluating the effectiveness of ICT
in locally advanced OPC using data from American National Cancer
Database found no improvement in OS [64]. Moreover, in subset
analysis, HPV-positive patients did not seem to benefit from ICT.
On the other hand, the poorest prognosis cohort – HPV-negative
individuals with T4 and/or N3 disease – seemed to benefit from
ICT [64]. Therefore, the panel of experts recommend concomitant
CRT for stage III to IVB – N0-2a tumors. In the subgroup of patients
N2b-c/N3, both concomitant CRT and ICT are recommended treat-
ment options although CRT was supported by greater consensus.
Regarding sequential treatment after ICT, continuance with cis-
platin plus RT entails high risk of acute and late toxicity, and might
cause radiation breaks and incomplete treatments [64–66,69].
NCCN guidelines recommend sequential treatment with either car-
boplatin or Cetuximab [10]. The authors prefer Cetuximab over
cisplatin-based CRT when ICT is given.
The panel agrees that concurrent CRT and/or ICT should not be
recommended in unfit patients (age 70 or greater, presence of
comorbidities, poor performance status) due to the high incidence
of toxicity - higher rates of hospitalization during treatment and
increased rates of acute mortality following CRT have been
reported - and due to the lack of clinical benefit and possible neg-
ative impact on survival, as meta-analysis and subgroup analysis
from prospective trials have suggested [67–69].
The recommendations for OPC are applicable to locally
advanced OCC when unresectable or when a non-surgical treat-
ment approach is chosen. Regarding the RT technique, the authors
agree that due to the lower toxicity profiles reported in several tri-
als, IMRT should be used [70,71].Disclosures
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